174 related articles for article (PubMed ID: 25818412)
21. Self-Emulsifying Drug Delivery System of Celecoxib for Avoiding Delayed Oral Absorption in Rats with Impaired Gastric Motility.
Yakushiji K; Sato H; Ogino M; Suzuki H; Seto Y; Onoue S
AAPS PharmSciTech; 2020 May; 21(5):135. PubMed ID: 32419073
[TBL] [Abstract][Full Text] [Related]
22. In vivo pharmacokinetics of celecoxib loaded endcapped PCLA-PEG-PCLA thermogels in rats after subcutaneous administration.
van Midwoud PM; Sandker M; Hennink WE; de Leede LGJ; Chan A; Weinans H
Eur J Pharm Biopharm; 2018 Oct; 131():170-177. PubMed ID: 30075312
[TBL] [Abstract][Full Text] [Related]
23. Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths.
Zhang Y; Che E; Zhang M; Sun B; Gao J; Han J; Song Y
Int J Pharm; 2014 Oct; 473(1-2):375-83. PubMed ID: 25051114
[TBL] [Abstract][Full Text] [Related]
24. Multifunctional porous silicon for therapeutic drug delivery and imaging.
Santos HA; Bimbo LM; Lehto VP; Airaksinen AJ; Salonen J; Hirvonen J
Curr Drug Discov Technol; 2011 Sep; 8(3):228-49. PubMed ID: 21291407
[TBL] [Abstract][Full Text] [Related]
25. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
[TBL] [Abstract][Full Text] [Related]
26. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS.
Lainé AL; Price D; Davis J; Roberts D; Hudson R; Back K; Bungay P; Flanagan N
Int J Pharm; 2016 Oct; 512(1):118-125. PubMed ID: 27543354
[TBL] [Abstract][Full Text] [Related]
27. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.
Araújo F; Shrestha N; Shahbazi MA; Fonte P; Mäkilä EM; Salonen JJ; Hirvonen JT; Granja PL; Santos HA; Sarmento B
Biomaterials; 2014 Nov; 35(33):9199-207. PubMed ID: 25109441
[TBL] [Abstract][Full Text] [Related]
28. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles.
Bimbo LM; Mäkilä E; Raula J; Laaksonen T; Laaksonen P; Strommer K; Kauppinen EI; Salonen J; Linder MB; Hirvonen J; Santos HA
Biomaterials; 2011 Dec; 32(34):9089-99. PubMed ID: 21864895
[TBL] [Abstract][Full Text] [Related]
29. Supersaturation of poorly soluble drugs induced by mesoporous magnesium carbonate.
Zhang P; Zardán Gómez de la Torre T; Welch K; Bergström C; Strømme M
Eur J Pharm Sci; 2016 Oct; 93():468-74. PubMed ID: 27590126
[TBL] [Abstract][Full Text] [Related]
30. Uniform mesoporous carbon as a carrier for poorly water soluble drug and its cytotoxicity study.
Zhao P; Wang L; Sun C; Jiang T; Zhang J; Zhang Q; Sun J; Deng Y; Wang S
Eur J Pharm Biopharm; 2012 Apr; 80(3):535-43. PubMed ID: 22193360
[TBL] [Abstract][Full Text] [Related]
31. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs.
Zhang Y; Wang J; Bai X; Jiang T; Zhang Q; Wang S
Mol Pharm; 2012 Mar; 9(3):505-13. PubMed ID: 22217205
[TBL] [Abstract][Full Text] [Related]
32. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs.
Wang F; Hui H; Barnes TJ; Barnett C; Prestidge CA
Mol Pharm; 2010 Feb; 7(1):227-36. PubMed ID: 19874003
[TBL] [Abstract][Full Text] [Related]
33. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs.
Salonen J; Laitinen L; Kaukonen AM; Tuura J; Björkqvist M; Heikkilä T; Vähä-Heikkilä K; Hirvonen J; Lehto VP
J Control Release; 2005 Nov; 108(2-3):362-74. PubMed ID: 16169628
[TBL] [Abstract][Full Text] [Related]
34. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
[TBL] [Abstract][Full Text] [Related]
35. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
36. Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability.
Niu X; Wan L; Hou Z; Wang T; Sun C; Sun J; Zhao P; Jiang T; Wang S
Int J Pharm; 2013 Aug; 452(1-2):382-9. PubMed ID: 23688621
[TBL] [Abstract][Full Text] [Related]
37. Preparation of novel porous starch microsphere foam for loading and release of poorly water soluble drug.
Jiang T; Wu C; Gao Y; Zhu W; Wan L; Wang Z; Wang S
Drug Dev Ind Pharm; 2014 Feb; 40(2):252-9. PubMed ID: 23391363
[TBL] [Abstract][Full Text] [Related]
38. Cellular interactions of surface modified nanoporous silicon particles.
Bimbo LM; Sarparanta M; Mäkilä E; Laaksonen T; Laaksonen P; Salonen J; Linder MB; Hirvonen J; Airaksinen AJ; Santos HA
Nanoscale; 2012 May; 4(10):3184-92. PubMed ID: 22508528
[TBL] [Abstract][Full Text] [Related]
39. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.
Nasr M
AAPS PharmSciTech; 2013 Jun; 14(2):719-26. PubMed ID: 23543607
[TBL] [Abstract][Full Text] [Related]
40. Effect of pore size of three-dimensionally ordered macroporous chitosan-silica matrix on solubility, drug release, and oral bioavailability of loaded-nimodipine.
Gao Y; Xie Y; Sun H; Zhao Q; Zheng X; Wang S; Jiang T
Drug Dev Ind Pharm; 2016; 42(3):464-72. PubMed ID: 26507935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
